Trial · NCT03126630
Adverse events504
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
1 to 20 of 504
Download this page as JSON| Type | Event | Organ system | Group | Affected | At risk | Events |
|---|---|---|---|---|---|---|
| other | Anemia | Blood and lymphatic system disorders | Phase 2 Group I (Pembrolizumab) | 7 | 17 | 42 |
| other | Anemia | Blood and lymphatic system disorders | Phase 2 Group II (Anetumab Ravtansine, Pembrolizumab) | 7 | 18 | 32 |
| other | Anemia | Blood and lymphatic system disorders | Phase 1 Cohort DLT 1 | 7 | 13 | 54 |
| other | Blood and lymph sys disorders - Oth Spec | Blood and lymphatic system disorders | Phase 2 Group I (Pembrolizumab) | 2 | 17 | 9 |
| other | Blood and lymph sys disorders - Oth Spec | Blood and lymphatic system disorders | Phase 2 Group II (Anetumab Ravtansine, Pembrolizumab) | 4 | 18 | 24 |
| other | Blood and lymph sys disorders - Oth Spec | Blood and lymphatic system disorders | Phase 1 Cohort DLT 1 | 1 | 13 | 12 |
| other | Cardiac disorders - Other, specify | Cardiac disorders | Phase 2 Group I (Pembrolizumab) | 0 | 17 | 0 |
| other | Cardiac disorders - Other, specify | Cardiac disorders | Phase 2 Group II (Anetumab Ravtansine, Pembrolizumab) | 1 | 18 | 3 |
| other | Cardiac disorders - Other, specify | Cardiac disorders | Phase 1 Cohort DLT 1 | 0 | 13 | 0 |
| other | Heart failure | Cardiac disorders | Phase 2 Group I (Pembrolizumab) | 1 | 17 | 1 |
| other | Heart failure | Cardiac disorders | Phase 2 Group II (Anetumab Ravtansine, Pembrolizumab) | 1 | 18 | 1 |
| other | Heart failure | Cardiac disorders | Phase 1 Cohort DLT 1 | 0 | 13 | 0 |
| other | Sinus bradycardia | Cardiac disorders | Phase 2 Group I (Pembrolizumab) | 1 | 17 | 1 |
| other | Sinus bradycardia | Cardiac disorders | Phase 2 Group II (Anetumab Ravtansine, Pembrolizumab) | 0 | 18 | 0 |
| other | Sinus bradycardia | Cardiac disorders | Phase 1 Cohort DLT 1 | 0 | 13 | 0 |
| other | Sinus tachycardia | Cardiac disorders | Phase 2 Group I (Pembrolizumab) | 2 | 17 | 2 |
| other | Sinus tachycardia | Cardiac disorders | Phase 2 Group II (Anetumab Ravtansine, Pembrolizumab) | 6 | 18 | 17 |
| other | Sinus tachycardia | Cardiac disorders | Phase 1 Cohort DLT 1 | 1 | 13 | 2 |
| other | Ear and labyrinth disorders - Oth spec | Ear and labyrinth disorders | Phase 2 Group I (Pembrolizumab) | 0 | 17 | 0 |
| other | Ear and labyrinth disorders - Oth spec | Ear and labyrinth disorders | Phase 2 Group II (Anetumab Ravtansine, Pembrolizumab) | 1 | 18 | 2 |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT03126630/events